ALLERGY THERAPEUTICS PLC

Business and Financial Review • Mar 12, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0671C

Allergy Therapeutics PLC

12 March 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

12 March 2014

Shareholder update

Allergy Therapeutics, the fully integrated specialty pharmaceutical company, announces that CFR Pharmaceutical SA ("CFR"), a company associated with the Weinstein family and the largest shareholder in Allergy Therapeutics, will today release its annual report for the year ended 31 December 2013.  In order that CFR can comply with its reporting requirements Allergy Therapeutics has made the following unaudited financial information below available to CFR.

Balance Sheet as at 30 September 2013

£ '000

Total Non-Current Assets         14,417

Total Current Assets                17,052

Total Current Liabilities            (9,863)

Total Non-Current Liabilities     (6,724)

Total Equity                            14,882

**Consolidated Income Statement for the 12 months ended 30 September 2013

**                                             £ '000

Revenue                                40,498

Profit for the period                      890

Items have the same meaning as disclosed in Allergy Therapeutics plc's accounts for the year ended 30 June 2013.

-Ends-

For further information

Allergy Therapeutics	+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Peel Hunt LLP	+44 (0) 20 7418 8900
James Steel
Clare Terlouw
FTI Consulting	+44 (0) 207 831 3113
Simon Conway
Victoria Foster Mitchell

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination.  It has a growing business achieving sales in the prior financial year of almost £40 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.  The Company is expanding its infrastructure into the Emerging Markets.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCGGUPUWUPCGBG